What is really going to happen with IRA impact on drug access in 2024 and 2025? How should pharma and biotech companies be preparing for future access to their treatments? As our industry enters the second year of the IRA provisions, biopharmaceutical companies are facing significant challenges to their access models: OOP caps, changes to Medicare Part D design, and the impact of this legislations to all stakeholders in the channel is starting to be felt. Hear from panelists across manufacturers, payers, and policy experts as they outline the upstream and downstream impacts of the implementation of IRA in the coming year and what your company can do to optimize access for your treatments no matter what stage of development you are in.